8 results
Objectives Primary end point:- to define the MTD of IL-2, subcutaneously given once a day, 5 days per week, for 6 weeks, in combination with a fixed dose of sorafenib in patients with metastatic RCC, clear cell subtype. Secondary end points:- the…
To describe and investigate safety and tolerability of the intradermal delivery of two fractional doses of 20 µg mRNA-1273 in patients with Fibrodysplasia Ossificans Progressiva.To compare the immunogenicity of patients with FOP after intradermal…
To assess immune response and adverse events after administration of one approved vaccine against COVID-19 in patients with cancer treated with immunotherapy and/or chemotherapy
To assess immunogenicity and safety of SARS-CoV-2 vaccination in patients with isolated antibody deficiencies, i.e. patients with immunoglobulin G (IgG) subclass deficiency and patients with selective antibody deficiency with normal immunoglobulins…
The primary objective of this study is to determine whether the addition of induction chemotherapy to the neoadjuvant treatment of patients with locally recurrent rectal cancer results in more R0 resections compared to treatment with neoadjuvant…
To study the effects of FCM on exercise tolerance, haematinic parameters, quality of life, cardiac function, muscle function, bone and mineral parameters, microbiota, the immune system, the incidence of infections, allograft failure and mortality in…
Objectives of the phase II study (80 patients) are to explore the feasibility of accrual, the feasibility, safety, and tolerance of perioperative systemic therapy, and the radiological and histological response of colorectal PM to neoadjuvant…
The purpose of this study is to investigate the efficacy and safety of the investigational drug known as Lutetium (177Lu) edotreotide in comparison with several other drugs that are already used worldwide in the treatment of neuroendocrine tumors.It…